Download PDF
Dtsch Med Wochenschr 2005; 130(45): 2579-2584
DOI: 10.1055/s-2005-922037
CME
Nephrologie / Pharmakologie
© Georg Thieme Verlag Stuttgart · New York

Nephrotoxische Arzneimittel

Nephrotoxic drugsD. Czock1 , U. Häußler1 , C. Aymanns1 , F. Keller1
  • 1Nephrologie, Medizinische Universitätsklinik, Ulm
Further Information

Publication History

eingereicht: 3.5.2005

akzeptiert: 28.7.2005

Publication Date:
04 November 2005 (online)

Also available at
   Permissions and Reprints
Zoom Image

Schlüsselwörter

CME - Nephrologie - Pharmakologie

Literatur

  • 1 Agrawal M, Stouffer G A. Contrast induced nephropathy after angiography.  Am J Med Sci. 2002;  323 252-258
    Google Scholar
  • 2 Anderson B J, Woollard G A, Holford N HG. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy.  Eur J Clin Pharmacol. 2001;  57 559-569
    Google Scholar
  • 3 Bader B D, Berger E D, Heede M B. et al . What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?.  Clin Nephrol. 2004;  62 1-7
    Google Scholar
  • 4 Birck R, Krzossok S, Markowetz F. et al . Acetylcysteine for prevention of contrast nephropathy: meta-analysis.  Lancet. 2003;  362 598-603
    Google Scholar
  • 5 Chang E J, Mun K C. Effect of epigallocatechin gallate on renal function in cyclosporine-induced nephrotoxicity.  Transplant Proc. 2004;  36 2133-2134
    Google Scholar
  • 6 Cheng H F, Harris R C. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors.  Curr Pharm Des. 2005;  11 1795-1804
    Google Scholar
  • 7 Deray G, Martinez F, Katlama C. et al . Foscarnet nephrotoxicity: mechanism, incidence and prevention.  Am J Nephrol. 1989;  9 316-321
    Google Scholar
  • 8 Elseviers M M, Waller I, Nenoy D. et al . Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe.  Nephrol Dial Transplant. 1995;  10 808-814
    Google Scholar
  • 9 Elseviers M M, De Broe M E. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance abuse?.  Drug Saf. 1999;  20 15-24
    Google Scholar
  • 10 Fillastre J P, Druet P, Mery J P. Proteinuric nephropathies associated with drugs and substances of abuse. Dekker, New York In The nephrotic syndrome (ed. Cameron JS, Glassock RJ) 1988: 697-744
    Google Scholar
  • 11 Gitlin M. Lithium and the kidney: an updated review.  Drug Saf. 1999;  20 231-243
    Google Scholar
  • 12 Kadikoylu G, Bolaman Z, Demir S. et al . The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys.  Hum Exp Toxicol. 2004;  23 29-34
    Google Scholar
  • 13 Kuypers D R, Neumayer H H, Fritsche L. et al . Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomised placebo-controlled 2-year study.  Transplantation. 2004;  78 1204-1211
    Google Scholar
  • 14 Lin J, Bonventre J V. Prevention of radiocontrast nephropathy.  Curr Opin Nephrol Hypertens. 2005;  14 105-110
    Google Scholar
  • 15 Lukas R, Eren A, Zellner D. et al . Furosemide after contrast media does no harm to the kidneys and allows for preventive hydration.  Perfusion. 2003;  16 326-333
    Google Scholar
  • 16 Merten G J, Burgess W P, Gray L V, Holleman J H, Roush T S, Kowalchuk G J, Bersin R M, Van Moore A, Simonton C A, Rittase R A, Norton H J, Kennedy T P. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;  291 2328-2334
    Google Scholar
  • 17 Mueller C, Buerkle G, Buettner H J. et al . Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty.  Arch Intern Med. 2002;  162 329-336
    Google Scholar
  • 18 Murphy S W, Barrett B J, Parfrey P S. Contrast nephropathy.  J Am Soc Nephrol. 2000;  11 177-182
    Google Scholar
  • 19 Nisar S, Feinfeld D A. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity.  Ren Fail. 2002;  24 529-533
    Google Scholar
  • 20 Nishino Y, Takemura S, Minamiyama Y. et al . Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats.  Free Radic Res. 2003;  37 373-379
    Google Scholar
  • 21 Olsen K M, Rudis M I, Rebuck J A. et al . Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity.  Crit Care Med. 2004;  32 1678-1682
    Google Scholar
  • 22 Ortiz M, Mon C, Fernandez M J. et al . Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib.  Nefrologia. 2005;  25 39-43
    Google Scholar
  • 23 Parfrey P S, Griffiths S M, Barrett B J. et al . Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study.  N Engl J Med. 1989;  320 143-149
    Google Scholar
  • 24 Parlakpinar H, Tasdemir S, Polat A. et al . Protective effect of chelerythrine on gentamicin-induced nephrotoxicity.  Cell Biochem Funct. 2004; 
    Google Scholar
  • 25 Potter J L, Krill C E. Acyclovir crystalluria.  Pediatr Infect Dis. 1986;  5 710-712
    Google Scholar
  • 26 Rudnick M R, Goldfarf S, Wexler l. et al . Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.  Kidney Int. 1995;  47 254-261
    Google Scholar
  • 27 Santoso J T, Lucci J A, Coleman R L. et al . Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomised trial.  Cancer Chemother Pharmacol. 2003;  52 13-18
    Google Scholar
  • 28 Sawyer M H, Webb D F, Balow J E. et al . Acyclovir induced renal failure: clinical course and histology.  Am J Med. 1988;  84 1067-1071
    Google Scholar
  • 29 Schadeli F, Marti H P, Frey F J. et al . Population pharmacokinetic model to predict steady-state exposure to once-daily Cyclosporin microemulsion in renal transplant recipients.  Clin Pharmacokinet. 2002;  41 59-69
    Google Scholar
  • 30 Schwarz A. Systematik der Nephrotoxizität. Wissenschaftliche Verlagsgesellschaft, Stuttgart In Nierenfunktion und Arzneimittel (ed. Deuber HJ, Keller F, Schwarz A) 2001: 150-259
    Google Scholar
  • 31 Schwarz A, Krause P H, Kunzendorf U. et al . The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis.  Clin Nephrol. 2003;  54 179-190
    Google Scholar
  • 32 Smith E J, Light J A, Filo R S. et al . Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients.  J Am Med Assoc. 1980;  244 360-361
    Google Scholar
  • 33 Sturmer T, Erb A, Keller F, Gunther K P, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications.  Am J Med. 2001;  1111 521-527
    Google Scholar
  • 34 Tepel M, van der Giet M, Schwarzfeld C. et al . Prevention of radiographic contrast agent-induced reductions in renal functions by acetylcysteine.  N Engl J Med. 2000;  343 180-184
    Google Scholar
  • 35 World M J, Stevens P E, Ashton M A. et al . Mesalazine-associated interstitial nephritis.  Nephrol Dial Transplant. 1996;  11 614-621
    Google Scholar

Prof. Dr. Frieder Keller

Sektionsleiter Nephrologie, Medizinische Universitätsklinik

Robert Koch-Straße 8

89070 Ulm

Phone: 0731/50024341

Fax: 0731/50024483

Email: frieder.keller@uni-ulm.de